WALTHAM, Mass., May 4, 2021 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:
SNDX), a clinical stage biopharmaceutical company developing an
innovative pipeline of cancer therapies, announced today that it
will release its first quarter 2021 financial results on
Tuesday, May 11, after the close of
the U.S. financial markets.
In connection with the earnings release, Syndax's management
team will host a conference call and live audio webcast at
4:30 p.m. ET on Tuesday, May 11, to
discuss the Company's financial results and provide a general
business update.
The live audio webcast and accompanying slides may be accessed
through the Events & Presentations page in the Investors
section of the Company's website at www.syndax.com. Alternatively,
the conference call may be accessed through the following:
Conference ID: 8178876
Domestic Dial-in Number: (855) 251-6663
International Dial-in Number: (281) 542-4259
Live webcast: https://edge.media-server.com/mmc/p/4gwngoxq
For those unable to participate in the conference call or
webcast, a replay will be available on the Investors section of the
Company's website, www.syndax.com.
About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies. The
Company's pipeline includes SNDX-5613, a highly selective inhibitor
of the Menin–MLL binding interaction, axatilimab, a monoclonal
antibody that blocks the colony stimulating factor 1 (CSF-1)
receptor, and entinostat, a class I HDAC inhibitor. For more
information, please visit www.syndax.com or follow the
Company on Twitter and LinkedIn.
Syndax Contacts
Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Benjamin Kolinski
GCI Health
Benjamin.Kolinski@gcihealth.com
Tel 862.368.4464
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-to-announce-first-quarter-2021-financial-results-and-host-conference-call-and-webcast-on-may-11-2021-301282838.html
SOURCE Syndax Pharmaceuticals, Inc.